Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$49.63 ▲ +0.38
(+0.77%)
MKT CAP: $2.96B • VOL: 2.28M
52W L $22 52W H $53
AXGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $225.2M | $187.3M | $159.0M |
| YoY Revenue Growth % | +20.2% | +17.8% | — |
| Gross Profit | $167.4M | $142.0M | $70.0M |
| Gross Margin % | 74.3% | 75.8% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.8M | -$3.3M | -$21.5M |
| Operating Margin % | -3.5% | -1.8% | -13.5% |
| Net Income (GAAP) | -$15.7M | -$10.0M | -$21.7M |
| EBITDA (Normalized) | -$4.9M | -$806.2K | -$15.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $812.0K | $4.5M | -$5.7M |
| Capital Expenditures (CapEx) | $3.7M | $3.1M | $7.2M |
| Free Cash Flow (FCF) | -$2.9M | $1.4M | -$12.9M |
| FCF Margin % | -1.3% | 0.8% | -8.1% |
| Return on Invested Capital (ROIC %) | -4.4% | -2.1% | -1.7% |
| Cash & Short-Term Equivalents | $35.5M | $27.6M | $179.3M |
| Total Debt (Short + Long Term) | $48.4M | $47.5M | $381.5M |
| Total Stockholders' Equity | $128.8M | $103.9M | $782.6M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AXGN.